By Turna Ray

A study published last week in the New England Journal of Medicine provides promising early results that a melanoma drug being developed by Roche and Plexxikon may be efficacious in patients carrying certain BRAF mutations.

However, according to the researchers, the study also suggests the need for more investigation to characterize the genetic complexities underlying patients' resistance to the investigational treatment and to determine whether the drug improves overall survival.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.